Dunlap, Garrett S. http://orcid.org/0000-0002-2627-0506
DiToro, Daniel
Henderson, Joel
Shah, Sujal I. http://orcid.org/0000-0002-0125-1448
Manos, Mike
Severgnini, Mariano
Weins, Astrid
Guleria, Indira
Ott, Patrick A. http://orcid.org/0000-0002-4253-943X
Murakami, Naoka http://orcid.org/0000-0001-8168-5811
Rao, Deepak A. http://orcid.org/0000-0001-9672-7746
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K08-AR072791, P30-AR070253, R01-CA229261, K08-DK120868, R03-DK131223)
U.S. Department of Health & Human Services | National Institutes of Health
Burroughs Wellcome Fund (N/A)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
American Society of Nephrology (N/A)
Article History
Received: 26 May 2022
Accepted: 8 March 2023
First Online: 21 March 2023
Competing interests
: P.A.O. has received research funding from and has advised Neon Therapeutics, Bristol-Myers Squibb, Merck, CytomX, Pfizer, Novartis, Celldex, Amgen, Array, AstraZeneca/ MedImmune, Armo BioSciences, Evaxion, Oncorus, Xencor, and Roche/Genentech.